Post-marketing surveillance should include effects during pregnancy

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7486.308-a (Published 03 February 2005) Cite this as: BMJ 2005;330:308
  1. Patricia Yeargin, associate medical editor, health promotions (yeargin2000@yahoo.com)
  1. American Cancer Society, 1599 Clifton Road, NE, Atlanta, GA 30329

    EDITOR—I agree that post-marketing surveillance of drugs is desperately needed.1 I further believe that, since information about drugs' effects during human gestation is never studied during pre-marketing, some post-marketing study of fetal effects during pregnancy should be considered.

    I have seen many women's medical care neglected during pregnancy owing to fear of harming the fetus, even when there is no real evidence …

    View Full Text

    Sign in

    Log in through your institution